■ Cover Story
Continued From Page 20 options . Health networks will also continue to invest more in population health strategies to keep people healthier and to reduce gaps in outcomes based on race and ethnicity .
Holy Name Medical Center Michael Maron , President and CEO
Holy Name is one of very few health systems nationally participating in the Centers for Medicare & Medicaid Services ’ Hospital at Home program . This enables Holy Name to use our advanced technology capabilities to bring acute inpatient care right into patients ’ homes . In the post-pandemic health environment , minimizing patients ’ exposure to potentially infectious diseases such as COVID , while providing world-class acute services in the comfort of patients ’ homes , could drastically alter the healthcare landscape for decades to come .
Jefferson Health — New Jersey Brian Sweeney , RN , MBA , FACHE , President and Chief Operating Officer
Labor shortages in the healthcare industry will require us to fundamentally redesign the care
Attracting and retaining skilled professionals will be a priority in healthcare institutions .
delivery model to meet consumer expectations . These challenges will lead to an acceleration of innovation . As a mitigation strategy , automation , robotics and artificial intelligence in ambulatory , hospital , surgery center and home care settings will evolve at a record pace .
Kessler Institute for Rehabilitation Sue Kida , President
Data shows that the pandemic resulted in many healthcare professionals leaving the field ,
Photo : Getty Images / iStockphoto / aona which is a concerning trend across the country . Being able to attract , engage and retain nurses , therapists and other clinical and support staff will be key to our continued success in meeting patients ’ complex rehabilitation needs in the years ahead .
Rutgers Cancer Institute of New Jersey Steven K . Libutti , M . D ., FACS , Director , Senior Vice President , Oncology Services , RWJBarnabas Health
Reengineering a patient ’ s own immune cells to fight cancer , an approach known as adoptive cell transfer , is changing the landscape of cancer therapy . Recently , a version of this approach , CAR T-cell therapy , received FDA approval to treat some blood cancers . At Rutgers Cancer Institute of New Jersey and RW- JBarnabas Health we are the only program in the state to not only offer CAR T-cell treatment , but with the Good Manufacturing Practices facility at our site , we will also be enhancing our work in this area and developing adoptive cell transfer therapies for common solid tumors . We look forward to contributing to the body of knowledge that will help these types of immune therapies to treat cancer patients in New Jersey and beyond .
Continued On Page 24
- CONTRACTORS - MANAGERS
411 Hackensack Ave , Hackensack , NJ 07645 Phone ( 201 ) 661-8390 Fax ( 201 ) 661-8386 www . jd-companies . com